Latest news

Our press releases and latest news

Here you will always find the latest news about Cannamedical® Pharma.



MedReleaf Corp. (TSX:LEAF) (“MedReleaf” or the “Company”), Canada’s first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH (“Cannamedical”), a leading medical cannabis distributor to pharmacies in Germany. MedReleaf will provide Cannamedical with monthly exports of five of its premium strain varieties significantly improving the predictability and security of drug delivery to the German market. Sales to Germany will commence promptly upon the expected receipt of MedReleaf’s European Medical Agency Good Manufacturing Practices (“GMP”) certification and export permit from Health Canada in the coming weeks.

Germany is poised to become the largest federally regulated medical cannabis market in the world, with a population of over 82 million, approximately 89% of whom are covered by the public health insurance program and the remainder covered by private insurance plans. The current medical cannabis laws in Germany came into effect on March 10, 2017 and without domestic production, cannabis is being imported to meet the rapidly growing demand.

“Federally legal markets for cannabis outside Canada are by and large focused on medical applications. This plays to MedReleaf’s core strengths in R&D, innovation, quality control, and pharmaceutical grade standards,” said Neil Closner, President and CEO. “Medical cannabis in Germany has been in short supply and Cannamedical is an ideal partner to bring MedReleaf’s premium cannabis products into Germany as one of Europe’s leading cannabis distributors with shared values on patient-centricity, a proven track record, and a growing network of 1,800 pharmacies.”

“We are very much looking forward to supply all patients in need of medication with premium quality cannabis produced by the leading Canadian cannabis producer. Both companies have grown in a strong and excellent partnership to implement all German GMP standards in close collaboration.” said David Henn, CEO.

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit or follow @medreleaf

About Cannamedical

Pioneering in the German cannabis industry, Cannamedical has been one of the first to specialize in highly efficient pharma distribution and marketing in accordance with the narcotics regulations. The privately-owned, GDP certified company holds all licenses required for medical cannabis import to Germany, distribution and export within the European Union. Cannamedical, as independent wholesaler has expertise in cannabis products and is serving an established and growing network of pharmacies all around the country.


On March 10th, 2018, the law “Cannabis as medicine” celebrates its first anniversary. For thousands of patients, the new law is a blessing. Thanks to the new law they benefit from the cannabis therapies which have to be paid by their health insurance companies. But not only from a health point of view does the cannabis law function like a European guidepost. A German company stands up for patients and is striving to ensure the European supply in the future.

The federal government had the courage to allow cannabis as medicine in Europe. Now it’s turning into a huge industry that will generate hundreds of new jobs and millions of euros in tax revenue in the near future.

At Cannamedical® Pharma GmbH, Germany´s leading independent cannabis wholesaler, 35 new permanent jobs were created for Cologne since the amendment of the law 12 months ago. And the potential is far from being exhausted. “We expect to create more than 350 new jobs within the next 24 months,” predicts David Henn, CEO of Cannamedical®

The independent wholesaler, based in Cologne, not only promotes better healthcare throughout Europe, but also offers innovative solutions to physicians and patients. Recently, Cannamedical® has entered a long-term partnership with one of Canada’s largest cannabis producers. “This partnership enables us to introduce up to 22 tons of high-quality cannabis to the European market by 2018,” says Niklas Kouparanis, the Sales Director of the company.

Last but not least, being based in Cologne is immensely important to Cannamedical® because of its cooperative supervisory authorities. The ongoing growth plans and the development of new sales markets could mean millions of euros for the city of Cologne in terms of tax revenues in the coming years.

Cannamedical® strives to strengthen the excellent cooperation between health insurance companies, importers and politicians in order to help Germany remain an internationally competitive business location and to improve the national job market.

“We are constantly reviewing production sites as we are looking to invest up to €20 million in a GMP-compliant, state-of-the-art manufacturing facility in the first expansion phase. In addition, Cannamedical® will invest another 10 million euros in cannabis research together with international partners over the next three years.

A large number of European countries have already created very attractive and inviting framework conditions for this, and another German location with comparable conditions could also be exciting. We are convinced that the cannabis agency will soon reach a decision regarding their public announcement on cannabis production from June 2017 and follow the example set by other European neighbors, “says Henn.

Download PDF

We’re here to help

Contact us

Our team of experts has a unique expertise and many years of professional experience.


Mo. – Fr. 8am-8pm
+49 221 / 999 852 – 00



Follow us

Social media

We are active on the following platforms.

Ihr Warenkorb